Suven Pharma to buy 67.5 percent stake in Sapala Organics for Rs 229.5 crore
Mumbai: Suven Pharmaceuticals has announced that the Company will acquire 67.5 per cent stake in Sapala Organics Private Limited for Rs 229.5 crore.
The Company has entered into a definitive agreement for a strategic controlling investment in Sapala Organics, subject to regulatory approvals and conditions, it stated in a release.
Suven to acquire 67.5% equity stake (i.e., 51% of the share capital of the Target on a fully diluted basis) for a consideration of Rs 2,295 mn subject to customary Working Capital and net debt adjustments, the Company stated in a BSE filing.
Suven to acquire a controlling stake initially whereas the existing shareholders of Sapala will continue to hold a significant minority stake for the next few years. Dr Reddy will continue to run the business as the CEO and also be associated with the Suven+Chance platform as a strategic advisor for the Japan market. Overall, 100% acquisition is expected to be in the range of 13-15x EBITDA multiple and is linked to the next three years’ financial performance.
"The company expects to complete the acquisition of 67.5% equity stake (i.e., 51% of the share capital of the Target on a fully diluted basis) during 2nd quarter of FY24- 25, subject to the completion of customary closing conditions. The company expects to complete the acquisition of remaining equity stake after FY2026-27, subject to the completion of customary closing conditions," Suven added.
Sapala is a Hyderabad based CDMO focused on Oligo drugs and nucleic acid building blocks including specialized/modified Amidites & Nucleosides, drug delivery compounds (including GalNAc), Pseudouridine, amongst others. Oligo & nucleic acid building blocks market is a ~$750M market and is expected to grow at a robust ~20% CAGR.
Sapala has experience in a comprehensive range of specialized building blocks. Sapala was founded by Dr P Yella Reddy who has extensive experience in nucleic acid chemistry and formerly worked as Director (R&D) with Aisin Cosmos R&D Co. Ltd (Toyota Group) in Japan & India for 20+ years. Sapala had a revenue of over INR 670mn and adjusted EBITDA margins of 45%+ for FY24.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.